0111 ECP Atalanta
BioCentury & Getty Images

Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

Emerging Company Profile: Newco launches with UMass Med’s branched siRNA tech, $110M in cash

Atalanta Therapeutics launches with UMass Medical’s branched siRNA technology and $110 million in cash from investor F-Prime and partners Biogen and Genentech.

Jan 12, 2021 | 2:05 AM GMT

A rush of interest following the publication of Atalanta’s

Read the full 693 word article

How to gain access

Continue reading with a
two-week free trial.